Today: Last Update:

 
 
 
 
 
 
 
 
 
  • Tennis Anti-Doping Programme Quarterly Report


    05/09/19

    On behalf of the seven stakeholders in the Tennis Anti-Doping Programme (TADP), the ITF has released the latest quarterly TADP report.

    These reports provide a regular source of information on the TADP to interested parties. The latest report contains information relating to Quarter 1 (January to March) of the 2019 TADP.

    The Tennis Anti-Doping Programme (TADP, or Programme) applies to all players who hold an ATP or WTA
    ranking, or who enter or compete in events organised, sanctioned or recognised by the ITF. The purposes of
    the Tennis Anti-Doping Programme are to maintain the integrity of tennis and protect the health and rights of
    all tennis players.

    Anti-Doping Working Group (ADWG) and Independent Review Board

    This group, which is responsible for overseeing the Programme, met in April. Among the matters discussed
    was a 2019 Programme status report, education initiatives, and a plan for the Programme for the next business
    cycle. The Independent Review Board, which is responsible for (among other things) determining whether any
    person covered under the Programme has a case to answer for a potential violation of the Programme, also
    held its annual meeting in April.

    Sample collection

    Testing statistics for quarter one are shown in the table below.
    2019 (Q1)                     Total samples    Men      Women
    In-Competition (urine)*   1,173                605       568
    In-Competition (blood)       20                 10            10
    In-Competition (ABP)          1                    1              0
    Out-of-Competition (urine) 356               177       179
    Out-of-Competition (blood) 348              173       175
    Out-of-Competition (ABP) 348               173        175

    Totals                              2,246             1,139       1,107

    Notes: the statistics in the above tables do not include samples collected by National Anti-Doping Organisations;
    ‘ABP’ refers to blood samples collected under the Athlete Biological Passport programme

    A total of 358 Out-of-Competition testing missions were attempted in Quarter 1 of 2019. Of these, a total of
    18 Missed Tests (which is an attempt to test a player during that player’s nominated 60-minute time slot,
    where the player was not available or accessible for testing) were declared. This represents 5% of all Out-of Competition missions in the Quarter.

    Sample storage
    The total number of samples placed into long-term storage under the TADP stands at 4,895. Samples are
    stored for the purposes of future analysis, such as in the event that new or more sensitive tests for prohibited
    substances are validated.

    Therapeutic Use Exemptions (TUEs)

    The TUE Committee comprises an international group of independent doctors. All TUE applications submitted
    under the Programme are anonymised prior to submission to the TUE Committee.

    Twenty-two TUE applications were reviewed by the TUE Committee under the Programme in the first quarter
    of 2018. Of those, 20 (91%) were granted, and 2 (9%) were denied.


    Education

    The TADP app was downloaded 363 times (a total of 2,841 since launch) and the ITF Knowledge education
    programme was completed 2,196 times (a total of 10,622 since launch). As part of the ongoing education
    provided under the programme, in-person support was provided to players participating in the ATP University
    in March. Warning notices were again posted to players regarding the risk of consuming contaminated meat
    in Mexico and China.

    Decisions
    Three decisions have been announced since the previous report:

    - Soyeon Park (KOR) was found to have committed an Anti-Doping Rule Violation under Article 2.1 of
    the Programme, on account of the positive sample provided by her on 17 June 2018, which contained
    phentermine. Phentermine is a non-specified stimulant. As a consequence, a period of ineligibility of
    thirteen months was imposed on her, back-dated to start from the date of sample collection.

    - Marcela Zacarias (MEX) was found to have committed an Anti-Doping Rule Violation under Article 2.1
    of the Programme, on account of the positive sample provided by her on 17 June 2018, which
    contained epitrenbolone, a metabolite of trenbolone. Trenbolone is a non-specified anabolic steroid.
    Ms. Zacarias was found to have no fault for the violation, as a consequence of which, no period of
    ineligibility was imposed on her.

    - Cesar Ramirez (MEX) was found to have committed an Anti-Doping Rule Violation under Article 2.1 of
    the Programme, on account of the positive sample provided by him on 12 April 2018, which contained
    metabolites of nandrolone, boldenone or boldenone-related steroids, drostanolone and stanozolol.
    Nandrolone, boldenone, drostanolone and stanozolol are non-specified anabolic steroids. As a
    consequence, a period of ineligibility of four years was imposed on him, back-dated to start from the
    date of sample collection.

    The number of Anti-Doping Rule Violations arising from samples collected in 2018 remains at four. All decisions
    can be found on the ITF Anti-Doping website.

    Retirements and reinstatements
    No players officially retired since the last report. No players have been reinstated from periods of retirement
    since the last report. 

    Media enquiries: communications@itftennis.com



    As a service to our readers, Around the Rings will provide verbatim texts of selected press releases issued by Olympic-related organizations, federations, businesses and sponsors.

    These press releases appear as sent to Around the Rings and are not edited for spelling, grammar or punctuation. 

    25 Years at #1: Your best source of news about the Olympics is www.aroundtherings.com, for subscribers only